open access

Vol 5, No 4 (2020)
Original article
Published online: 2020-11-03
Get Citation

Changes of substance P, NGF and CGRP salivary levels among patients undergoing physical therapy

Witold Miecznikowski1, Sylwia Mielcarska2, Paweł Kiczmer2, Karolina Cygan3, Elżbieta Świętochowska2
DOI: 10.5603/MRJ.a2020.0041
·
Medical Research Journal 2020;5(4):238-243.
Affiliations
  1. Department of Orthopaedics,Medical University of Silesia, Trauma Centre, Plac Medyków 1, 41-200 Sosnowiec, Poland
  2. Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-800 Zabrze, Poland
  3. Niepubliczny Wielospecjalistyczny Zakład Opieki Zdrowotnej, Grota Roweckiego 179, 41-200 Sosnowiec, Poland

open access

Vol 5, No 4 (2020)
ORIGINAL ARTICLES
Published online: 2020-11-03

Abstract

Pain is one of the most prevalent health conditions in the world. It is widely accepted that chronic pain persists beyond its biological usefulness and compromises the quality of life. Chronic pain is not only continuum of acute pain, but effect of functional and structural reorganization in central nervous system (CNS) and changes in perception and behaviour. The aim of our study was to investigate salivary levels of NGF, CGRP and substance P and assess changes in pain intensity among patients suffering from cervical spine pain or CSD-related headaches before and after physical therapy. Study group consisted of 86 patients. 44 were treated using McKenzie method and 42 of them underwent suboccipital relaxation therapy. To determine the salivary concentration of Substance P, CGRP, NGF the commercially available enzyme-linked immunosorbent assay kit were used. The intensity of pain was assessed using VAS score. In both groups we observed significant decrease in VAS score and Substance P concentration after treatment. In McKenzie group there was a significant increase in NGF level after therapy; the changes in CGRP level were not significant. In group undergoing suboccipital relaxation we found significant reduction of concentration of all investigated molecules: Substance P, CGRP and NGF. Both methods influence the conditions of patients through decrease in VAS score and changes in salivary levels of Substance P, CGRP and NGF. Further research is needed to completely elucidate the influence of McKenzie method and suboccipital relaxation on pain markers levels.

Abstract

Pain is one of the most prevalent health conditions in the world. It is widely accepted that chronic pain persists beyond its biological usefulness and compromises the quality of life. Chronic pain is not only continuum of acute pain, but effect of functional and structural reorganization in central nervous system (CNS) and changes in perception and behaviour. The aim of our study was to investigate salivary levels of NGF, CGRP and substance P and assess changes in pain intensity among patients suffering from cervical spine pain or CSD-related headaches before and after physical therapy. Study group consisted of 86 patients. 44 were treated using McKenzie method and 42 of them underwent suboccipital relaxation therapy. To determine the salivary concentration of Substance P, CGRP, NGF the commercially available enzyme-linked immunosorbent assay kit were used. The intensity of pain was assessed using VAS score. In both groups we observed significant decrease in VAS score and Substance P concentration after treatment. In McKenzie group there was a significant increase in NGF level after therapy; the changes in CGRP level were not significant. In group undergoing suboccipital relaxation we found significant reduction of concentration of all investigated molecules: Substance P, CGRP and NGF. Both methods influence the conditions of patients through decrease in VAS score and changes in salivary levels of Substance P, CGRP and NGF. Further research is needed to completely elucidate the influence of McKenzie method and suboccipital relaxation on pain markers levels.

Get Citation

Keywords

Substance P; CGRP, NGF; McKenzie therapy; suboccipital relaxation

About this article
Title

Changes of substance P, NGF and CGRP salivary levels among patients undergoing physical therapy

Journal

Medical Research Journal

Issue

Vol 5, No 4 (2020)

Article type

Original article

Pages

238-243

Published online

2020-11-03

Page views

395

Article views/downloads

587

DOI

10.5603/MRJ.a2020.0041

Bibliographic record

Medical Research Journal 2020;5(4):238-243.

Keywords

Substance P
CGRP
NGF
McKenzie therapy
suboccipital relaxation

Authors

Witold Miecznikowski
Sylwia Mielcarska
Paweł Kiczmer
Karolina Cygan
Elżbieta Świętochowska

References (30)
  1. Zieglgänsberger W. Substance P and pain chronicity. Cell Tissue Res. 2019; 375(1): 227–241.
  2. Kuner R, Flor H, Kuner R, et al. Structural plasticity and reorganisation in chronic pain. Nat Rev Neurosci. 2016; 18(1): 20–30.
  3. Martimbianco AL, Porfírio GJm, Pacheco RL, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain. Cochrane Database Syst Rev. 2019; 12: CD011927.
  4. Han DS, Lee CH, Shieh YD, et al. Involvement of Substance P in the Analgesic Effect of Low-Level Laser Therapy in a Mouse Model of Chronic Widespread Muscle Pain. Pain Med. 2019; 20(10): 1963–1970.
  5. Yoon JS, Park J, Song R, et al. Substance P as a potential biomarker of pain assessment in dogs. Iran J Vet Res. 2019; 20(4): 289–292.
  6. Jessell TM. Substance P in nociceptive sensory neurons. Ciba Found Symp. 1982(91): 225–248.
  7. Kelleher JH, Tewari D, McMahon SB. Neurotrophic factors and their inhibitors in chronic pain treatment. Neurobiol Dis. 2017; 97(Pt B): 127–138.
  8. da Silva JT, Evangelista BG, Venega RAG, et al. Anti-NGF treatment can reduce chronic neuropathic pain by changing peripheral mediators and brain activity in rats. Behav Pharmacol. 2019; 30(1): 79–88.
  9. Denk F, Bennett DL, McMahon SB. Nerve Growth Factor and Pain Mechanisms. Annu Rev Neurosci. 2017; 40: 307–325.
  10. Schmelz M, Mantyh P, Malfait AM, et al. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019; 160(10): 2210–2220.
  11. Greco R, Demartini C, Zanaboni AM, et al. Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing. J Headache Pain. 2018; 19(1): 51.
  12. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(9): 895–926.
  13. Schou WS, Ashina S, Amin FM, et al. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017; 18(1): 34.
  14. Cubała A, Hoffman J, Hagner W, et al. Effect of McKenzie method on the severity and location of pain in patients with lumbo-sacral discopathy. Medical and Biological Sciences. 2012; 26(4).
  15. Szulc P, Wendt M, Waszak M, et al. Impact of McKenzie Method Therapy Enriched by Muscular Energy Techniques on Subjective and Objective Parameters Related to Spine Function in Patients with Chronic Low Back Pain. Med Sci Monit. 2015; 21: 2918–2932.
  16. Namnaqani FI, Mashabi AS, Yaseen KM, et al. The effectiveness of McKenzie method compared to manual therapy for treating chronic low back pain: a systematic review. J Musculoskelet Neuronal Interact. 2019; 19(4): 492–499.
  17. Yang DJ, Kang DaH. Comparison of muscular fatigue and tone of neck according to craniocervical flexion exercise and suboccipital relaxation in cervicogenic headache patients. J Phys Ther Sci. 2017; 29(5): 869–873.
  18. Miecznikowski W, Kiczmer P, Cygan K, et al. Cortisol, testosterone, and pain levels among patients undergoing McKenzie therapy and suboccipital relaxation. Medical Research Journal. 2020; 5(1): 34–40.
  19. Hökfelt T, Pernow B, Wahren J. Substance P: a pioneer amongst neuropeptides. J Intern Med. 2001; 249(1): 27–40.
  20. Hökfelt T, Kellerth JO, Nilsson G, et al. Substance p: localization in the central nervous system and in some primary sensory neurons. Science. 1975; 190(4217): 889–890.
  21. O'Connor TM, O'Connell J, O'Brien DI, et al. The role of substance P in inflammatory disease. J Cell Physiol. 2004; 201(2): 167–180.
  22. Bazzichi L, Giacomelli C, Consensi A, et al. One year in review 2020: fibromyalgia. Clin Exp Rheumatol. 2020; 38 Suppl 123(1): 3–8.
  23. Karatay S, Okur SC, Uzkeser H, et al. Effects of Acupuncture Treatment on Fibromyalgia Symptoms, Serotonin, and Substance P Levels: A Randomized Sham and Placebo-Controlled Clinical Trial. Pain Med. 2018; 19(3): 615–628.
  24. Field T, Diego M, Cullen C, et al. Fibromyalgia pain and substance P decrease and sleep improves after massage therapy. J Clin Rheumatol. 2002; 8(2): 72–76.
  25. Chen WN, Chen CC. Acid mediates a prolonged antinociception via substance P signaling in acid-induced chronic widespread pain. Mol Pain. 2014; 10: 30.
  26. Chang CT, Jiang BY, Chen CC. Ion Channels Involved in Substance P-Mediated Nociception and Antinociception. Int J Mol Sci. 2019; 20(7).
  27. Lin JH, Hung CH, Han DS, et al. Sensing acidosis: nociception or sngception? J Biomed Sci. 2018; 25(1): 85.
  28. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24(7): 539–548.
  29. Zhang Y, Gong S, He Li, et al. Nerve growth factor for neuropathic pain. Cochrane Database Syst Rev. 2017.
  30. Patel MK, Kaye AD, Urman RD. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018; 34(1): 111–116.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.